

RESEARCH

Open Access



The fraction of life years lost after diagnosis (FLYLAD): a person-centred measure of cancer burden

David Banham^{1,2*} , Jonathan Karnon³, Alex Brown^{2,4}, David Roder⁵ and John Lynch¹

Abstract

Background Cancer control initiatives are informed by quantifying the capacity to reduce cancer burden through effective interventions. Burden measures using health administrative data are a sustainable way to support monitoring and evaluating of outcomes among patients and populations. The Fraction of Life Years Lost After Diagnosis (FLYLAD) is one such burden measure. We use data on Aboriginal and non-Aboriginal South Australians from 1990 to 2010 to show how FLYLAD quantifies disparities in cancer burden: between populations; between sub-population cohorts where stage at diagnosis is available; and when follow-up is constrained to 24-months after diagnosis.

Method FLYLAD_{cancer} is the fraction of years of life expectancy lost due to cancer (YLL_{cancer}) to life expectancy years at risk at time of cancer diagnosis (LYAR) for each person. The Global Burden of Disease standard life table provides referent life expectancies. FLYLAD_{cancer} was estimated for the population of cancer cases diagnosed in South Australia from 1990 to 2010. Cancer stage at diagnosis was also available for cancers diagnosed in Aboriginal people and a cohort of non-Aboriginal people matched by sex, year of birth, primary cancer site and year of diagnosis.

Results Cancers diagnoses ($N = 144,891$) included 777 among Aboriginal people. Cancer burden described by FLYLAD_{cancer} was higher among Aboriginal than non-Aboriginal (0.55, 95% CIs 0.52–0.59 versus 0.39, 95% CIs 0.39–0.40). Diagnoses at younger ages among Aboriginal people, 7 year higher LYAR (31.0, 95% CIs 30.0–32.0 versus 24.1, 95% CIs 24.1–24.2) and higher premature cancer mortality (YLL_{cancer} = 16.3, 95% CIs 15.1–17.5 versus YLL_{cancer} = 8.2, 95% CIs 8.2–8.3) influenced this. Disparities in cancer burden between the matched Aboriginal and non-Aboriginal cohorts manifested 24-months after diagnosis with FLYLAD_{cancer} 0.44, 95% CIs 0.40–0.47 and 0.28, 95% CIs 0.25–0.31 respectively.

Conclusion FLYLAD described disproportionately higher cancer burden among Aboriginal people in comparisons involving: all people diagnosed with cancer; the matched cohorts; and, within groups diagnosed with same staged disease. The extent of disparities were evident 24-months after diagnosis. This is evidence of Aboriginal peoples' substantial capacity to benefit from cancer control initiatives, particularly those leading to earlier detection and treatment of cancers. FLYLAD's use of readily available, person-level administrative records can help evaluate health care initiatives addressing this need.

Keywords Indigenous Australians, Cancer, Premature mortality, Mortality to incidence ratio, Disparity, Burden of disease

*Correspondence:

David Banham

david.banham@adelaide.edu.au

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Cancer is a leading cause of death and premature death globally [1, 2]. In Australia, cancer remains the largest contributor to years of life prematurely lost (YLL) despite the age standardised burden per head of population having declined by 11% from 2003 to 2011 [3]. Average burden may mask disparate trends in outcomes between and within populations [4, 5]. In the case of Aboriginal Australians (where “Aboriginal” is respectfully used to refer to people self-identifying as Aboriginal, Torres Strait Islander, or both [6]) comparable age-adjusted YLL were initially higher (52 versus 35 YLL per 1,000 population in 2003) and further increased to 55 versus 31 YLL per 1,000 population by 2013. This higher fatal burden is influenced by comparatively greater incidence of cancers with poor survival [5, 7, 8], diagnoses at more advanced stage [9–11], lower exposure to cancer treatment [9, 12], and excess case fatality concentrated in the first two years after diagnosis [13]. Each of these influences suggest an unmet capacity to benefit from cancer control initiatives and actions including augmented cancer screening programs and addressing variations in treatment [14–16]. While clinical aspects of cancer care are the same for everyone, irrespective of cultural heritage, optimal care should also deliver services that are culturally safe and responsive [17]. Such interventions need to be accompanied by relevant performance measures; measures which ensure system accountability [18], first by articulating disparity, then quantifying the capacity to benefit from prevention, early detection and intervention.

At a macro-level, performance measures for population cancer outcomes [19] usually use relative survival [7, 20]. Relative survival is the ratio of observed survival among a group of people diagnosed with cancer and the expected survival of a similar, disease free group in the general population [21]. However, that method’s use can be severely limited for sub-populations of particular interest [7, 22, 23] or greatest need [23] where life tables detailing the background probabilities of death are not routinely available [24]. Such is the case with Aboriginal Australians, particularly at state and territory levels [7, 25]. An alternative is to use the Mortality to Incidence Ratio (MIR) which is the ratio of the observed cancer mortality and incidence rates in a given population in a specified time period [26, 27]. MIR is often used to illustrate disparate cancer outcomes between countries [28, 29] and the manner in which health system ranking [30] with components of cancer care such as cancer screening and treatment [29, 31–34], positively correlate with better, lower MIRs as illustrated in Fig. 1 [28]. Australia’s health system is ranked thirty-second by the World Health Organization and has an average MIR of approximately 0.3, which is low by international standards and reflects well on Australia’s cancer control activities [35]. While less frequently used, MIR also describes cancer disparities within countries [36–38]. In this light, the favourable Australian average masks Aboriginal Australia’s poorer outcome of 0.5 [39].

MIR has limited application for routine performance reporting for several reasons. As with life tables [7, 22,




Fig. 1 Mortality to Incidence Ratio (MIR) by the World Health Organization’s Health System ranking (Top 100)

23], routine and/or localised estimates for calculating population incidence and mortality rates may not be readily accessible. This is the case for Aboriginal Australians with Census estimates before 2016 labelled as 'experimental' and yearly population updates by age and smaller geographical areas not routinely published [40]. Consequently, data availability also limits the use of MIR [41] in quantifying opportunities to tailor initiatives to the needs of relevant sub-populations [42]. In addition, population [43] and cancer registrations [5, 44] available for performance monitoring often have time lags of two years or more before their release. This is sub-optimal because disparities in cancer outcome are manifest within 24-months of diagnosis [13]. Earlier signals on outcomes are needed if we are to evaluate the effects of system change in a timely manner [45, 46].

We respond to the need to further develop performance measurement in cancer control by revising MIR with the aim of increasing comparison between and within population sub-groups and without relying on infrequently available population parameters. We do so by employing a burden of disease method and measuring the time gap [47] against optimal life expectancy [48] remaining at two critical points in a person's experience of cancer: the age of a person's cancer diagnosis and death from cancer. Optimal life expectancy here refers to an international standard derived from the best observed mortality rates globally [49]. By adopting this method we re-evaluate the MIR's underlying parameters at the person level, then aggregate results for (sub)population groups.

Consequently, we introduce the Fraction of Life Years Lost After Diagnosis (FLYLAD), a metric that reframes MIR within a burden of disease method. After outlining FLYLAD's components and construction, we provide four analyses demonstrating its application. *Analysis One* focuses on general disparities in cancer burden existing between populations and uses cancers diagnosed among Aboriginal and non-Aboriginal Australians. Given these populations experience differences in age and primary site of cancers diagnosed [5, 8], *Analysis Two* adjusts for those confounding variables and quantifies disparity between Aboriginal people with cancer and a matched cohort of cancer cases drawn from the non-Aboriginal population. *Analysis Three* enumerates differences in FLYLAD within the Aboriginal and matched non-Aboriginal cohorts on the basis of cancer stage at diagnosis. To assess the extent to which disparities in cancer burden are evident soon after diagnosis, our final *Analysis Four* evaluates cancer burden between and within the matched cohorts 24-months after diagnosis. We then consider the implications and responses to observed disparities.

Methods

Study design and participants

We first provide a population context of all cancer cases [excluding non-melanoma skin cancer] diagnosed among South Australians in the period 1990 to 2010 ($N=144,891$). A nested retrospective, matched cohort design [9, 50] is used to compare cancers cases diagnosed among Aboriginal people ($N=777$) with a one-to-one random selection of cancer cases among non-Aboriginals matched on the basis of sex, year of birth, primary cancer site and year of diagnosis [8]. Follow-up time is from diagnosis date to date of death, or censoring or records at 31 December 2011, whichever occurred first.

Data sources, related measurements and definition of FLYLAD

Cancer data for the South Australian population were obtained from the South Australian Cancer registry (SACR) [51] in the course of developing an advanced cancer data system within the Cancer Data and Aboriginal Disparities (CanDAD) project [52]. SACR is a population registry collating dates of International Classification of Diseases for Oncology (ICD-O-3) [53] coded diagnoses and death (attributed as cancer or non-cancer death). Specialist clinical cancer registry staff further enhanced the nested cohort study records using diagnostic and pathology records available to SACR to include cancer stage at diagnosis using Surveillance, Epidemiology, and End Results Program methodologies [54]. Stage at diagnosis categories included: *localised*—confined to tissue of origin; *regional*—invaded adjacent tissue or regional nodes; *distant/unknown*—spread to distant lymph nodes or other organ sites; leukaemia; or insufficient staging data were available.

MIR parameters of mortality and incidence are reframed within a burden of disease framework in the following manner. Mortality among cancer cases is quantified using YLL [55, 56], the amount of life expectancy remaining at time at which death attributed to cancer occurred. Incidence is quantified using expected Life Years at Risk (LYAR) [57], that is, the amount of life expectancy remaining at time at which cancer diagnosis occurred. Both YLL and LYAR represent the years of optimal life expectancy remaining at the age a given event occurs. That optimal life expectancy, which is subsequently used as a standard to which other measures refer, was previously derived for the global burden of disease study using the lowest age-specific risk of death observed in populations greater than 5 million individuals across the world [55] (Table 1). In the case of YLL, the relevant event is the age at death while LYAR refers to age at diagnosis.

Table 1 Cancer diagnoses, premature mortality

Age (years)	Life expectancy (years)
0	86.6
1	85.8
5	81.8
10	76.8
15	71.9
20	66.9
25	62.0
30	57.0
35	52.1
40	47.2
45	42.4
50	37.6
55	32.9
60	28.3
65	23.8
70	19.4
75	15.3
80	11.5
85	8.2
90	5.5
95	3.7
100	2.6
105	1.6
110	1.4

Reproduced from Appendix Table 18, p. 503 [54]. 10.1016/S0140-6736(17)32152-9 licenced under CC BY 4.0

We make three assumptions in adopting those standard life expectancy estimates. First, we assume it is fair that all people aspire to optimal life expectancy because health differentials between sub-populations are influenced through societal and environmental risk factor exposures [48, 49] rather than fixed biological determinants aside from age. Second, we assume a uniform estimate of life expectancy across time, place and circumstance facilitates fair comparisons, regardless of changing geographic or sub-population specific mortality rates. We also assume a consistent method to deriving measures facilitates comparison between those measures, and that such comparisons are valuable.

FLYLAD represents the amount of life expectancy lost as a fraction of life expectancy remaining at the time a sentinel health event is diagnosed, and expressed as a decimal. In the case of premature loss of life from cancer death after cancer diagnosis (FLYLAD_{cancer}), this is the ratio of years of life lost attributed to cancer (YLL_{cancer}) to expected life years at risk at the time of cancer diagnosis (LYAR) represented as:

$$FLYLAD_{cancer} = \frac{YLL_{cancer}}{LYAR}$$

As a fraction of YLL and LYAR, FLYLAD ranges from 0, where death after cancer diagnosis does not occur within the observation period, to 1, where death occurs at the same age as diagnosis. As an example, a person diagnosed with cancer at age 55 is taken as having 32.9 years of life expectancy remaining, thus LYAR is 32.9. Where death from cancer follows at age 65 the remaining life expectancy represents 23.8 years of life lost to cancer, YLL_{cancer}. FLYLAD_{cancer} is 23.8/32.9, or 0.72, indicating that 72% of life expectancy at time of diagnosis was subsequently lost.

Individual FLYLAD, and its LYAR and YLL components, can be grouped across population groups, or cohorts of people diagnosed with cancer. FLYLAD can refer to a variety of observation periods. For instance, populations or cohorts may be observed for: varying periods from time of diagnosis to right-censoring of observations at a given date; a fixed period after cancer diagnosis; or, a combination of the two.

Statistical analysis

Under the heading of *Risk*, we summarise the mean age at cancer diagnosis and the accompanying LYAR. Subsequent *Loss* to premature mortality describes the number and mean age of deaths observed and attributed to cancer. Where deaths were not attributed to cancer, YLL_{cancer} is zero.

Table 2 includes three groups of cancer cases: the population of cancer cases diagnosed from 1990 to 2010 among non-Aboriginal South Australians; cancer cases diagnosed among Aboriginal South Australians in the same period; and, a matched cohort of cancer cases among non-Aboriginal people. Table 3 focuses on the Aboriginal and non-Aboriginal cohorts disaggregated by stage at diagnosis. Table 4 repeats this focus while limiting observation time to a maximum of 24-months after diagnosis.

Our multivariable analysis used the matched cohorts to evaluate the relationship between: FLYLAD_{cancer} at 24-months after diagnosis (FLYLAD_{cancer 24-months}) as the outcome with Aboriginality as the exposure and, cancer stage at diagnosis as a covariate. Interactions between Aboriginality and stage at diagnosis were also examined. We used fractional response regression [58], a quasi-likelihood estimation method available within Stata 15.1 as *fracreg* [59], and assumed a probit model for the conditional mean. This approach accommodates FLYLAD's attributes as: a fraction of two continuous quantities with life expectancy lost as numerator, life expectancy at time of diagnosis as denominator; having a denominator

Table 2 Cancer diagnoses, premature mortality and FLYLAD_{cancer} South Australia 1990–2010

	Cases among non-Aboriginal				Cases among Aboriginal				Matched cases among non-Aboriginal [#]			
	N	%	Mean	95% CIs	N	%	Mean	95% CIs	N	%	Mean	95% CIs
<i>Risk</i>												
Age at diagnosis (years)	144,114	100.0%	65.5	65.4–65.6	777	100.0%	57.7	56.6–58.8	777	100.0%	58.5	57.4–59.5
Life years at risk (LYAR)			24.1	24.1–24.2			31.0	30.0–32.0			30.3	29.3–31.3
<i>Loss</i>												
Cancer deaths* and age (years)	62,936	43.7%	71.7	71.6–71.8	461	59.3%	61.5	60.2–62.9	340	43.8%	63.7	62.1–65.2
Years of life lost from cancer (YLL _{cancer})			8.2	8.2–8.3			16.3	15.1–17.5			11.2	10.1–12.3
<i>Fraction of loss: risk</i>												
Fraction of life years lost after diagnosis (FLYLAD _{cancer})			0.39	0.39–0.40			0.55	0.52–0.59			0.40	0.37–0.44

Among observations right-censored at 31/12/2011

[#] Randomly selected cancer cases among non-Aboriginal people matched one to one with cases among Aboriginal by sex, year of birth, year of diagnosis and primary cancer site

which is also the maximum value for the numerator; and, thus having values in the range of 0 to 1 inclusive. We clustered the data by the cohorts’ matched pairs and report 95% confidence intervals (95% CIs) based on robust standard errors. We report the modelled parameter coefficients which provide the sign of each covariate’s effect on FLYLAD_{cancer 24-months}. However, because the coefficients are difficult to interpret we also assessed the simultaneous average marginal effects of Aboriginality and stage at diagnosis on the fraction of life at risk lost in the 24-month period from diagnosis. That is, we report the change in FLYLAD_{cancer 24-months} where the cancer case involved an Aboriginal person rather than non-Aboriginal; and localised or distant stages rather than regional stage disease at diagnosis.

Results

Cancer burden between population groups

Table 2 shows SACR recorded 144,891 invasive cancer diagnoses among South Australians from 1990 to 2010. Cancer diagnoses among Aboriginal people accounted for a small number of those cases (N=777) and these are described in detail elsewhere [8]. Notably though, the latter cases were diagnosed at considerably younger age (57.7 years) compared to those among non-Aboriginal people (65.5 years). Consequently, life expectancy at risk at time of cancer diagnosis was almost 7 years higher among Aboriginal people with LYAR=31.0 (95% CIs 30.0–32.0) compared to the non-Aboriginal average of LYAR=24.1 (95% CIs 24.1–24.2). Proportionately more case fatalities, and at younger average age, were also observed among Aboriginal people with cancer. Taken together, average loss to premature mortality from cancer among Aboriginal cases was twice that of the broader

group of non-Aboriginal cases (YLL_{cancer} = 16.3, 95% CIs 15.1–17.5 versus YLL_{cancer} = 8.2, 95% CIs 8.2–8.3). In turn, FLYLAD_{cancer} was markedly higher among Aboriginal compared to non-Aboriginal cases at 0.55 (95% CIs 0.52–0.59) versus 0.39 (95% CIs 0.39–0.40) respectively.

Cancer burden between and within matched cohorts

Table 2 also compares cases among Aboriginal people compared to a randomly selected cohort of diagnoses among non-Aboriginal cases (N=777) matched by sex, year of birth, year of diagnosis and primary cancer site [8]. LYAR among the Aboriginal and non-Aboriginal cohort are therefore equivalent because of age matching. Fewer case fatalities at comparatively older ages among the non-Aboriginal cohort led to an average YLL_{cancer} at 11.2 (95% CIs 10.1–12.3) and FLYLAD_{cancer} at 0.40 (95% CIs 0.37–0.44) which were markedly lower than their matched Aboriginal contemporaries with FLYLAD_{cancer}=0.55 (95% CIs 0.52–0.59). Indeed, FLYLAD_{cancer} for all non-Aboriginal and the subset of cases within the non-Aboriginal cohort were very similar (0.39, 95% CIs 0.39–0.40 and 0.40, 95% CIs 0.37–0.44 respectively).

Table 3 disaggregates Aboriginal and matched non-Aboriginal cohort results by stage at diagnosis. Cancers among Aboriginal people were more likely to involve distantly spread disease (n=333 or 42.8% of cases) than among non-Aboriginal people (n=255 or 32.8% of cases). Within each stage at diagnosis cancer case fatality was relatively more common among Aboriginal than non-Aboriginal people. Also, the average age at cancer death was lower among Aboriginal people than non-Aboriginal people diagnosed with regionally staged disease (58.9 versus 63.1 years) and distant staged disease (60.8

Table 3 Cancer diagnoses, premature mortality and FLYLAD_{cancer} by stage at diagnosis, South Australia 1990–2010

	Localised at diagnosis						Regional spread at diagnosis						Distant/Unknown spread at diagnosis											
	Aboriginal		Matched non-Aboriginal [#]		Aboriginal		Matched non-Aboriginal [#]		Aboriginal		Matched non-Aboriginal [#]		Aboriginal		Matched non-Aboriginal [#]									
	N	%	Mean	95% CIs	N	%	Mean	95% CIs	N	%	Mean	95% CIs	N	%	Mean	95% CIs								
<i>Risk</i>																								
Age at diagnosis	289	100.0%	58.4	56.5–60.3	390	100.0%	57.8	56.2–59.3	155	100.0%	55.5	53.2–57.8	132	100.0%	57.9	55.4–60.5	333	100.0%	58.1	56.4–59.8	255	100.0%	59.8	57.9–61.7
LYAR			30.4	28.7–32.2			30.9	29.5–32.4			32.8	30.7–34.9			30.7	28.4–33.0			30.6	29.1–32.1			29.1	27.4–30.8
<i>Loss</i>																								
Cancer deaths*	101	34.9%	65.9	63.0–68.9	100	25.6%	64.9	61.6–68.2	93	60.0%	58.9	56.1–61.7	59	44.7%	63.1	59.6–66.7	267	80.2%	60.8	59.1–62.6	181	71.0%	63.2	61.1–65.2
YLL _{cancer}			8.3	6.7–9.9			6.3	5.0–7.6			17.8	15.1–20.6			11.6	9.0–14.2			22.5	20.8–24.3			18.5	16.6–20.4
<i>Fraction of loss: risk</i>																								
FLYLAD _{cancer}			0.30	0.25–0.35			0.22	0.18–0.26			0.56	0.49–0.64			0.41	0.33–0.49			0.77	0.73–0.81			0.68	0.62–0.73

Randomly selected cancer cases among non-Aboriginal people matched one to one with cases among Aboriginal by sex, year of birth, year of diagnosis and primary cancer site

* Among observations right-censored at 31/12/2011

Table 4 Cancer diagnoses, premature mortality and FLYLAD_{cancer} at 24-months by stage at diagnosis, South Australia 1990–2010

	All cancers															
	Localised at diagnosis						Distant/unknown spread at diagnosis									
	Aboriginal		Matched non-Aboriginal [#]		Aboriginal		Matched non-Aboriginal [#]		Aboriginal		Matched non-Aboriginal [#]					
N	%	Mean	95% CIs	N	%	Mean	95% CIs	N	%	Mean	95% CIs	N	%	Mean	95% CIs	
<i>Risk</i>																
Age at diagnosis	777	100.0%	57.7	56.6–58.8	777	100.0%	58.5	57.4–59.5	289	100.0%	58.4	56.5–60.3	390	100.0%	57.8	56.2–59.3
LYAR			31.0	30.0–32.0			30.3	29.3–31.3			30.4	28.7–32.2			30.9	29.5–32.4
<i>Loss</i>																
Cancer deaths _{24-months} [*]																
Age at death _{cancer 24-months}	346	44.5%	60.4	58.9–61.9	224	28.8%	63.5	61.6–65.4	51	17.6%	63.0	58.5–67.5	40	10.3%	64.4	59.3–69.4
YLL _{cancer 24-months}			12.7	11.5–13.9			7.4	6.5–8.4			4.7	3.3–6.0			2.6	1.7–3.5
<i>Fraction of loss: risk</i>																
FLYLAD _{cancer 24-months}			0.44	0.40–0.47			0.28	0.25–0.31			0.17	0.13–0.21			0.10	0.07–0.13
	Regional spread at diagnosis						Distant/unknown spread at diagnosis									
	Aboriginal		Matched non-Aboriginal [#]		Aboriginal		Matched non-Aboriginal [#]		Aboriginal		Matched non-Aboriginal [#]					
	N	%	Mean	95% CIs	N	%	Mean	95% CIs	N	%	Mean	95% CIs	N	%	Mean	95% CIs
<i>Risk</i>																
Age at diagnosis	155	100.0%	55.5	53.2–57.8	132	100.0%	57.9	55.4–60.5	333	100.0%	58.1	56.4–59.8	255	100.0%	59.8	57.9–61.7
LYAR			32.8	30.7–34.9			30.7	28.4–33.0			30.6	29.1–32.1			29.1	27.4–30.8
<i>Loss</i>																
Cancer deaths _{24-months} [*]																
Age at death _{cancer 24-months}	67	43.2%	58.5	55.2–61.8	37	28.0%	63.4	58.4–68.3	228	68.5%	60.4	58.5–62.3	147	57.6%	63.3	61.0–65.6
YLL _{cancer 24-months}			13.0	10.3–15.7			7.2	4.9–9.6			19.5	17.7–21.4			15.0	13.0–16.9
<i>Fraction of loss: risk</i>																
FLYLAD _{cancer 24-months}			0.42	0.35–0.50			0.27	0.20–0.35			0.68	0.63–0.72			0.57	0.51–0.63

Among observations right-censored at a maximum of 24 months after diagnosis or 31/12/2011

[#] Randomly selected cancer cases among non-Aboriginal people matched one to one with cases among Aboriginal by sex, year of birth, year of diagnosis and primary cancer site

versus 63.2 years). Both factors contributed to markedly greater average YLL_{cancer} in the Aboriginal cohort than the non-Aboriginal cohort with differences ranging from 2.0 (95% CIs 1.7–2.3) in localised stage to 6.2 (6.1–6.2) in regionally spread disease. For both cohorts, $FLYLAD_{cancer}$ increased as cancer spread at diagnosis increased. However, $FLYLAD_{cancer}$ also showed the relative amount of life at risk and subsequently lost was higher within the Aboriginal cohort at each stage of disease at diagnosis.

Cancer burden two years after diagnosis

Table 4 shows cohort outcomes up to two years after cancer diagnosis. Case fatality increased as stage at diagnosis increased from local to regional to distant stages with consistently higher loss observed among Aboriginal compared to non-Aboriginal people. Again, age at cancer death was younger among Aboriginal people than non-Aboriginal people for each stage at diagnosis. Average YLL_{cancer} was also higher among Aboriginal cases at each stage of disease at diagnosis. Consequently, $FLYLAD_{cancer}$ differed between cohorts 24-months after diagnosis with higher losses among Aboriginal ($FLYLAD_{cancer\ 24-months} = 0.44$, 95% CIs 0.40–0.47) than non-Aboriginal ($FLYLAD_{cancer\ 24-months} = 0.28$, 95% CIs 0.25–0.31). This difference of 0.16 in the limited 24-month follow-up period (using $FLYLAD_{cancer\ 24-months}$) was very similar to the difference of 0.15 observed across the full observation period (using $FLYLAD_{cancer}$).

$FLYLAD_{cancer\ 24-months}$ also differed within cohorts and increased as stage at diagnosis increased. For example, point estimates for $FLYLAD_{cancer\ 24-months}$ within the Aboriginal cohort increased from 0.17 in cases of localised disease to 0.68 where disease spread was distant or unknown, an overall change of 0.51. Overall change

within the non-Aboriginal cohort was slightly less at 0.47 and ranged from 0.10 in localised disease to 0.57 in distant spread disease.

Multivariable analysis

Table 5 shows the association between life at risk and life subsequently lost up to 24-months after cancer diagnosis in the cohorts and the concurrent effects of Aboriginality and stage at diagnosis. Both Aboriginality and advancing disease stage at diagnosis were associated with higher $FLYLAD_{cancer}$. The model’s marginal effects indicate Aboriginal cases experienced an average of 0.10 or 10% (95% CIs 0.06–0.14) higher $FLYLAD_{cancer}$ than non-Aboriginal cohort cases diagnosed with the same stage of disease. Simultaneously, and when compared to regionally spread disease at diagnosis, localised disease was associated with 0.21 or 21% (95% CIs 0.14–0.27) lower $FLYLAD_{cancer}$ and distant/unknown spread with 0.27 or 27% (95% CIs 0.20–0.34) higher $FLYLAD_{cancer}$. No further interaction of the effects of Aboriginality by stage at diagnosis was evident.

Discussion

$FLYLAD$ combines life expectancy at the time of cancer diagnosis and the resultant loss of life due to cancer death to quantify cancer burden. This is calculated for each person diagnosed with subsequent aggregation to groups. Our first analysis demonstrated $FLYLAD$ ’s application in describing disparities in cancer burden for the entire population of invasive cancers diagnosed among South Australians. $FLYLAD$ described substantially higher cancer burden among the population of Aboriginal people with cancer compared to other South Australians ($FLYLAD_{cancer}$ of 0.55 versus 0.39). These differences were bought about by Aboriginal South Australians with cancer having lower average age and more life expectancy

Table 5 Fractional outcome regression and average marginal effects on $FLYLAD_{cancer}$ at 24-months, South Australia 1990–2010

	Model for $FLYLAD_{cancer\ 24-months}$				Average marginal effects [#]			
	Coef	95% CIs	z	$p > z $	dy/dx	95% CIs	z	$p > z $
<i>Aboriginal</i>								
No	0.00	Reference			0.00	Reference		
Yes	0.33	0.21–0.45	5.46	<0.001	0.10	0.06–0.14	5.43	<0.001
<i>Stage at diagnosis</i>								
Localised	–0.72	–0.92–0.53	–7.38	<0.001	–0.21	–0.27–0.14	–6.92	<0.001
Regional	0.00	Reference			0.00	Reference		
Distant/unknown	0.70	0.52–0.89	7.48	<0.001	0.27	0.20–0.34	7.81	<0.001
Constant	–0.56	0.30–0.52	–6.67	<0.001				

Using a randomly selected cancer cases among non-Aboriginal people matched one to one with cases among Aboriginal by sex, year of birth, year of diagnosis and primary cancer site with observations right censored at a maximum of 24 months after diagnosis or at 31/12/2011

[#] Average marginal effects represent the change in $FLYLAD_{cancer\ 24-months}$, the outcome variable, when moving from a predictor variable’s reference category

(7 years) at risk of loss while also experiencing higher average premature mortality loss due to higher case fatality (59.3% versus 43.7%) and younger age at death (62 versus 72 years). Our second analysis focussed on Aboriginal and non-Aboriginal cohorts with equivalent sex, age, year of diagnosis and primary cancer site. While life expectancy at diagnosis was equivalent, FLYLAD enumerated 15% more cancer burden among Aboriginal South Australians with cancer (FLYLAD_{cancer} of 0.55 versus 0.40). This was influenced by more frequent cancer deaths (59.3% versus 43.8%) and these deaths being at a younger age (61.5 versus 63.7 years). With the availability of stage at diagnosis for the cohorts, we then considered the variation of cancer burden within the cohorts. In both cohorts FLYLAD increased as stage increased from local to regional to distant spread. In addition, FLYLAD remained higher among Aboriginal people at each stage (FLYLAD_{cancer}=0.30 versus 0.22 for localised disease; 0.56 versus 0.41 for regional spread; and, 0.77 versus 0.68 for distant spread). These disparities by stage and Aboriginality were not only apparent for the broader observation period. They were fully manifested 24-months after diagnosis and our fourth analysis showed 16% higher cancer burden among Aboriginal than non-Aboriginal contemporaries (FLYLAD_{cancer 24-months} of 0.44 versus 0.28 respectively). Disparity of this size then continued across longer term observations.

Our analyses align with other reports of MIR, the ratio of observed cancer mortality and incidence rates in a given population in a specified time period,

which describe intra-country disparities in cancer outcomes. For example, MIR differences between Black (MIR=0.48) and White (MIR=0.40) in South Carolina are clear [36, 38], yet recent differences between Aboriginal (MIR=0.51) and Australia generally (MIR=0.30) are even more pronounced [39]. These disparate results are echoed by FLYLAD within the population of South Australians diagnosed with cancer where substantially more cancer burden among Aboriginal than non-Aboriginal (FLYLAD_{cancer}=0.55 versus 0.39 respectively) was quantified.

There are notable points of difference between MIR and FLYLAD though and Table 6 summarises strengths and limitations of each. MIR makes use of mortality and incidence rates calculated on people diagnosed or dying in any given period. Those dying may have been diagnosed in different time periods meaning different groups of people are being compared [20]. One consequence of back-scattering incident cases is to make it difficult to observe rapid changes in prognosis [20]. FLYLAD however, draws directly on each individual case for both denominator (LYAR) and numerator (YLL). Because incidence and mortality are observed within the same person the need to adjust for back-scattering is avoided. This is an advantage because it enables FLYLAD to provide an earlier signal on cancer outcomes. Earlier measures can inform timely evaluations of system change, particularly system change aimed at improving outcomes within 24-months of diagnosis, a time when disparities are entrenched but also able to be detected using FLYLAD.

Table 6 Strengths and limitations of MIR and FLYLAD measures

Strengths	Limitations
<i>MIR</i>	
Familiar measure with history of use	
Uses frequently available incidence and mortality rates	Requisite incidence, mortality and population level data not always available
	Evaluated at population level with potential variation in time periods and back-scattering
<i>FLYLAD</i>	
Components evaluated against an optimal standard	New measure derived from internationally established burden of disease framework
Numerator and denominator evaluated at individual, person level	Evaluation against an optimal standard can overestimate disparities open to short term change
Separate components evaluate time: at risk and lost	No back-scattering
Potential to include quality of life perspective within life at risk component	
MIR and FLYLAD	
Offers a relative perspective on health inequality	Interpretation of changes in relative measures can be difficult
Imperfect, yet offers transparent method to quantification	Measure selection requires assessment against the relevant information need and application

FLYLAD's perspective on cancer burden is relevant to evidence-based policy development in cancer control [60] in other ways. For example, FLYLAD's estimation provides absolute measures of life at risk and life lost from cancer in a manner that is useful to planning activities. This is achieved by anchoring age at diagnosis and age at cancer death against a defined, optimal outcome. By describing disparities in age at diagnosis, LYAR determined the amount of life expectancy amenable to change by preventing cancer, or at least deferring cancer incidence to later ages, through reduced exposure to cancer risks. As a relative measure, FLYLAD revealed disparities across stage at diagnosis where more advanced disease led to higher cancer mortality and higher FLYLAD. This information can help prioritise activities leading to earlier case detection and increased participation in cancer screening activities to detect cancers at an earlier stage. FLYLAD also demonstrated an ability to enumerate disparities in cancer burden associated with stage and ancestry 24-months after cancer diagnosis, a time during which people are more likely to be receiving care through health services [46]. This becomes particularly useful in supporting activities that promote access [61], uptake and quality [15, 62] of effective and available cancer treatments. In short, FLYLAD enumerates people's capacity to benefit from cancer control initiatives involving prevention, early detection and treatment and thus contributes to prioritising health system activities.

Similarly, while we report aggregated outcomes, it is important to remember FLYLAD is calculated for each individually diagnosed case which become available for grouping and analysed in many configurations. We grouped observations by Aboriginality, however groups could be based on: shared area level geography; socio-economic position; or, by attending a certain service or receiving the care of particular providers. This adaptability is not only relevant to policy and planning but has further application in relating system performance to outcomes for individuals and the population groups to whom they belong [42]. FLYLAD offers a robust and contemporary measure of performance with which to assess the effectiveness of early detection and treatment efforts. This is because FLYLAD is free of the immediate need for background population information and time lags in reporting are reduced with counting and observations beginning as soon as diagnosis is made. This suggests the use of clinical records for reporting at patient (micro) and service (meso) levels in the first instance. As the underlying cancer and mortality records are integrated into population registries as we have used, macro-level reporting for populations and the whole of system can follow. Information at these varying levels lend themselves to continued quality improvement processes and ongoing

applied research. The use of existing, routine administrative data also helps address the evaluation needs of health services and government [63] while promoting public accountability [64]. Indeed, incorporating YLL within FLYLAD facilitates comparison with other health system indicators and targets around reducing avoidable and premature mortality, particularly among vulnerable populations [64].

FLYLAD has other strengths. Our analyses demonstrate the feasibility of assessing FLYLAD using existing, routine, administrative and/or clinical records which also suggests it is readily sustainable. Other parameters from hospital systems could inform stratification within patient groups, for example, by stage at diagnosis. As cancer mortality outcomes improve and it becomes increasingly important to assess patient morbidity, the burden of disease method also provides for health adjusting the age relevant life expectancy and incorporating this into FLYLAD estimates [57, 65]. In the meantime, FLYLAD responds to the call for ever-increasing comparability and granularity in reporting [65] in two ways. We showed FLYLAD's comparability across populations and within small cohort groups. Further comparison with the wider Australian community, or even globally and for other time periods is quite possible because by measuring against the same, global standard. FLYLAD has additional scope to generalise across conditions such as stroke or heart attack where there are definitive times of diagnosis enabling assessment of LYAR and subsequent YLL components. This would inform further comparison between and within people groups based on health condition.

Limitations

FLYLAD has several limitations. Interpreting relative outcome measures expressed as fractions which depend on different numerators and denominators is challenging. It is also a commonly occurring issue when considering issues of health disparity [66]. Our suggested response is to accompany FLYLAD with reports of LYAR and YLL as absolute measures based on life expectancy. This raises the major limitation of FLYLAD in that both LYAR and YLL are predicated on a global standard life table while local life expectancy for population groups of interest will likely be different. That is, FLYLAD makes use of two biased measures and overestimates outcome disparities [67, 68] suggesting a prudent approach to its use as recommended with other survival methods [69]. The counter argument is to avoid bias by using population specific life tables [70–72]. However, life tables reflecting jurisdiction or group averages do not necessarily remedy the issue because such averages may mask considerable variation within the relevant jurisdictions or population

Table 7 Examples of applying FLYLAD to policy goals

Baseline		Goal 1: defer incidence and death by 5 years		Goal 2: defer incidence by 5 years and add a further 5 years to survival	
Cancer diagnosis at age 55	LYAR = 32.9	Cancer diagnosis at age 60	LYAR = 28.3	Cancer diagnosis at age 60	LYAR = 28.3
Cancer death at age 65	YLL _{cancer} = 23.8 FLYLAD = 0.72	Cancer death at age 70	YLL _{cancer} = 19.4 FLYLAD = 0.69	Cancer death at age 75	YLL _{cancer} = 15.3 FLYLAD = 0.54

group. For example, average life expectancy within one US county having the benefit of one of the highest observed life expectancies at birth was recently shown to subsume variations of up to 18 years among males and 15 years for females [73]. Nevertheless, when relevant life tables become available, the bias within our analysis can be approximated as done in other instances assessing the need for intra-country socio-economic position life tables [69]. Until such time though, our analysis makes use of the fall-back recommendation of using cancer specific mortality. This is justified because where health inequities exist, it is unacceptable to wait until complete information is to hand before acting. Therefore, we adopt an imperfect but well based and transparent method to quantifying health inequity by measuring against a gold standard, optimal outcome. In our case, this outcome is a standard attained by some but markedly less so by others within the same country and served by the same universal, healthcare system.

We further acknowledge our analysis of FLYLAD did not account for the influence of comorbid conditions [74, 75]. These are a major point of difference in the health status of Aboriginal and other Australians. However, FLYLAD estimates for all-causes of death among people with cancer are easily calculated. Where higher risk of death from non-cancer causes are experienced [24] FLYLAD estimates would increase and potentially exacerbate the disparities we documented. Other cancer survival studies do in fact report changes in the risk of death from cancer or non-cancer causes in the five years after cancer diagnosis [24] and this issue will benefit from further investigation.

In the meantime, FLYLAD has current applications in describing, then monitoring progress towards new cancer control goals. For example, from a given baseline position, say diagnosis at age 55 and cancer death 10 years later, FLYLAD is 0.72 (Table 7). A first policy goal may be to defer the incidence of cancer by five years with a similar, 10-year survival time. In that case, LYAD reduces, YLL reduces slightly more, so the FLYLAD fraction also reduces to 0.69. FLYLAD and its components each reflect progress in health outcomes in line with the policy goal. Having deferred cancer incidence, a second goal may be to extend survival time after cancer by

5 years. In this case, LYAR is unchanged, YLL decreases further and reflects the outcome consistent with the policy goal. FLYLAD also decreases to 0.54 and shows progress towards lower cancer burden for an individual.

Conclusion

We demonstrated FLYLAD’s application in quantifying cancer burden disparities using Aboriginal and non-Aboriginal comparisons in South Australia. Cancer burden was markedly higher among Aboriginal people than non-Aboriginal in all comparisons based on: all people diagnosed with cancer; groups matched by sex, age, primary site and year of diagnosis; and, within groups experiencing similarly staged disease at diagnosis. Importantly, the extent of disparities were evident 24-months after diagnosis and persisted at similar levels thereafter. This points to a substantial capacity to benefit from improved cancer control initiatives among Aboriginal people, particularly those health system activities aimed at earlier detection and treatment of cancers. Our analyses also suggest FLYLAD’s use of readily available, person-level information can provide important information helping evaluate person-centred cancer care as one dimension of high-quality health care delivery addressing this need.

Abbreviations

95% CIs	95% Confidence intervals
CanDAD	Cancer Data and Aboriginal Disparities
FLYLAD	Fraction of Life Years Lost After Diagnosis calculated as YLL/LYAR for each case and expressed as a decimal
FLYLAD _{cancer}	Fraction of Life Years Lost After Diagnosis calculated as YLL _{cancer} /LYAR for each case
FLYLAD _{cancer 24-months}	Fraction of Life Years Lost After Diagnosis up to 24-months after diagnosis calculated as YLL _{cancer 24-months} /LYAR for each case
LYAR	Life Years at Risk
PROMs	Patient Reported Outcome Measures
SACR	South Australian Cancer Registry
YLL	Years of Life Lost
YLL _{cancer}	Years of Life Lost associated with cancer death
YLL _{cancer 24-months}	Years of Life Lost associated with cancer death up to 24-months after diagnosis

Acknowledgements

Dr. Graeme Tucker for statistical advice and the Cancer Data and Aboriginal Disparities (CanDAD) Aboriginal Community Reference Group (ACoRG), particularly Aunty Roslyn Weetra.

Author contributions

DB conceived the project, performed the analyses and drafted the manuscript; JL, JK, AB and DR made important contributions to operationalising this study, interpreting the statistical analysis, and revised the manuscript. All authors read and approved the final version of the manuscript.

Funding

The CanDAD project was funded by National Health and Medical Research Council (APP1072243), Cancer Council SA's Beat Cancer Project with project partners' in-kind support. DB is supported in part by an Australian Government Research Training Program Scholarship. AB is supported by the Sylvia and Charles Viertel Senior Medical Research Fellowship. The funders were not involved in the analysis, data interpretation and writing of this manuscript.

Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available due to privacy reasons, including the provisions of the Australian Privacy Principles. The study's data comprised of de-identified unit record administrative records and were used under privileged arrangements set out in a study specific confidentiality deed. The data cannot be accessed by another party without relevant data custodian and human research ethics approvals.

Declarations

Ethics approval and consent to participate:

South Australia's Aboriginal Health Research Ethics Committee (AHREC 04-12-461) and SA Health's Human Research Ethics Committee (SA Health HREC HREC/12/SAH/35) approved the use of population cancer registry records. CanDAD's Aboriginal Community Reference Group governance ensured alignment of the study protocol with South Australian Aboriginal Health Research Accord principles [76].

Consent for publication

Not applicable.

Competing interests

The authors declare they have no competing interests.

Author details

¹School of Public Health, University of Adelaide, North Terrace, Adelaide, SA 5000, Australia. ²Wardliparingga Aboriginal Health Research, South Australian Health and Medical Research Institute, North Terrace, Adelaide, SA 5000, Australia. ³College of Medicine and Public Health, Flinders University, Sturt Road, Bedford Park, SA 5042, Australia. ⁴Faculty of Health and Medical Sciences, University of Adelaide, North Terrace, Adelaide, SA 5000, Australia. ⁵School of Health Sciences, Cancer Research Institute, University of South Australia, North Terrace, Adelaide, SA 5000, Australia.

Received: 20 March 2019 Accepted: 7 September 2023

Published online: 13 September 2023

References

- Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulkader RS, Abdulle AM, Abebo TA, Abera SF, Aboyans V, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet*. 2017;390:1260–344.
- Global Burden of Disease Cancer Center. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. *JAMA Oncol*. 2017;3:524–48.
- Australian Institute of Health and Welfare. Australian Burden of Disease Study: Impact and causes of illness and death in Australia 2011. Canberra: AIHW; 2016.
- Cancer in Aboriginal & Torres Strait Islander people of Australia. <https://www.aihw.gov.au/reports/cancer/cancer-in-indigenous-australians/report-editions>.
- Australian Institute of Health and Welfare. Cancer in aboriginal and Torres Strait islander peoples of Australia: an overview. Canberra: AIHW; 2013.
- Health Performance Council Secretariat. Monitoring the implementation of transforming health indicator report. Adelaide: Government of South Australia; 2017.
- Condon JR, Zhang X, Baade P, Griffiths K, Cunningham J, Roder DM, Coory M, Jelfs PL, Threlfall T. Cancer survival for Aboriginal and Torres Strait Islander Australians: a national study of survival rates and excess mortality. *Popul Health Metrics*. 2014;12:25.
- Banham D, Roder D, Keefe D, Farshid G, Eckert M, Cargo M, Brown A. for the CanDAD Aboriginal Community Reference Group and other CanDAD investigators: Disparities in cancer stage at diagnosis and survival of Aboriginal and non-Aboriginal South Australians. *Cancer Epidemiol*. 2017;48:131–9.
- Valery P, Coory M, Stirling J, Green A. Cancer diagnosis, treatment, and survival in Indigenous and non-Indigenous Australians: a matched cohort study. *Lancet*. 2006;367:1842–8.
- Condon J, Cunningham J, Barnes A, Armstrong B, Selva-Nayagam S. Cancer diagnosis and treatment in the Northern Territory—assessing health service performance for Indigenous Australians. *Intern Med J*. 2006;36:498–505.
- Roder D. Comparative cancer incidence, mortality and survival in Indigenous and non-Indigenous residents of South Australia and the Northern Territory. *Cancer Forum*. 2005;29:7–9.
- Condon J, Armstrong B, Barnes A, Cunningham J. Cancer in Indigenous Australians: a review. *Cancer Causes Control*. 2003;14:109–21.
- Cramb S, Garvey G, Valery P, Williamson J, Baade P. The first year counts: cancer survival among Indigenous and non-Indigenous Queenslanders, 1997–2006. *Med J Aust*. 2012;196:270–4.
- Adelson P, Fusco K, Karapetis C, Wattchow D, Joshi R, Price T, Sharplin G, Roder D. Use of guideline-recommended adjuvant therapies and survival outcomes for people with colorectal cancer at tertiary referral hospitals in South Australia. *J Eval Clin Pract*. 2017.
- Liu JB, Ko CY. Disparities in rectal cancer: moving from descriptions to solutions. *Ann Surg Oncol*. 2017;24:299–301.
- Woods LM, Rachet B, Coleman MP. Origins of socio-economic inequalities in cancer survival: a review. *Ann Oncol*. 2006;17:5–19.
- Cancer Australia. Optimal care pathway for Aboriginal and Torres Strait Islander people with cancer. Sydney: Cancer Australia; 2018.
- Lancet T. What's next for Indigenous health in Australia? *The Lancet*. 2018;391:632.
- Clauser SB. Use of cancer performance measures in population health: a macro-level perspective. *JNCI Monogr*. 2004;2004:142–54.
- Ellis L, Woods LM, Esteve J, Eloranta S, Coleman MP, Rachet B. Cancer incidence, survival and mortality: explaining the concepts. *Int J Cancer*. 2014;135:1774–82.
- Ederer F, Axtell LM, Cutler SJ. The relative survival rate: A statistical methodology. *Natl Cancer Inst Monogr*. 1961;6:101–21.
- Mariotto AB, Noone A-M, Howlader N, Cho H, Keel GE, Garshell J, Woloshin S, Schwartz LM. Cancer survival: an overview of measures, uses, and interpretation. *JNCI Monographs*. 2014;2014:145–86.
- Morris M, Woods LM, Rachet B. A novel ecological methodology for constructing ethnic-majority life tables in the absence of individual ethnicity information. *J Epidemiol Community Health*. 2015;69:361–7.
- He VY, Condon JR, Baade PD, Zhang X, Zhao Y. Different survival analysis methods for measuring long-term outcomes of Indigenous and non-Indigenous Australian cancer patients in the presence and absence of competing risks. *Popul Health Metr*. 2017;15:1.
- Australian Bureau of Statistics. Life tables for Aboriginal and Torres Strait Islander Australians: 2010–2012. Canberra: ABS; 2013.
- Suwanrungruang K, Sriplung H, Temiyasathit S, Waisri N, Daoprasert K, Kamsa-Ard S, Tasanapitak C, McNeil E. Appropriateness of the standard mortality/incidence ratio in evaluation of completeness of population-based cancer registry data. *Asian Pac J Cancer Prev*. 2011;12:3283–8.
- Asadzadeh Vostakolaei F, Karim-Kos HE, Janssen-Heijnen MLG, Visser O, Verbeek ALM, Kiemeny LALM. The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. *Eur J Public Health*. 2011;21:573–7.

28. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136:E359–86.
29. Choi E, Lee S, Nhung BC, Suh M, Park B, Jun JK, Choi KS. Cancer mortality-to-incidence ratio as an indicator of cancer management outcomes in Organization for Economic Cooperation and Development countries. *Epidemiol Health*. 2017;39:e2017006.
30. World Health Organization. The World Health Report 2000: Health systems—improving performance. Geneva: WHO; 2000. p. 1–177.
31. Sunkara V, Hébert JR. The colorectal cancer mortality-to-incidence ratio as an indicator of global cancer screening and care. *Cancer*. 2015;121:1563–9.
32. Doubova SV, Pérez-Cuevas R. Going further to measure improvements in health-care access and quality. *The Lancet*. 2018;391:2190–2.
33. Fullman N, Yearwood J, Abay SM, Abbafati C, Abd-Allah F, Abdela J, Abdelalim A, Abebe Z, Abebo TA, Aboyans V, et al. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. *The Lancet*. 2018;391:2236–71.
34. Chen S-L, Wang S-C, Ho C-J, Kao Y-L, Hsieh T-Y, Chen W-J, Chen C-J, Wu P-R, Ko J-L, Lee H, Sung W-W. Prostate cancer mortality-to-incidence ratios are associated with cancer care disparities in 35 countries. *Sci Rep*. 2017;7:40003.
35. Australia C. National cancer control indicators (NCCI) framework. Sydney: Cancer Australia; 2017.
36. Hébert JR, Daguise VG, Hurley DM, Wilkerson RC, Mosley CM, Adams SA, Puett R, Burch JB, Steck SE, Bolick-Aldrich SW. Mapping cancer mortality-to-incidence ratios to illustrate racial and sex disparities in a high-risk population. *Cancer*. 2009;115:2539–52.
37. Hashim D, Manczuk M, Holcombe R, Lucchini R, Boffetta P. Cancer mortality disparities among New York City's Upper Manhattan neighborhoods. *Eur J Cancer Prev*. 2017;26:453–60.
38. Babatunde OA, Adams SA, Eberth JM, Wirth MD, Choi SK, Hebert JR. Racial disparities in endometrial cancer mortality-to-incidence ratios among Blacks and Whites in South Carolina. *Cancer Causes Control*. 2016;27:503–11.
39. Australian Cancer Incidence and Mortality (ACIM) books: all cancers combined. <http://www.aihw.gov.au/acim-books>.
40. Australian Bureau of Statistics. Estimates and projections, aboriginal and Torres Strait Islander Australians: 2001 to 2026. Canberra: ABS; 2014.
41. Parkin D, Hakulinen T. Analysis of survival. In: Jensen O, Parkin D, MacLennan R, Muir C, Skeet RL, editors. *Cancer registration: principles and methods*. Lyon: International Agency for Research on Cancer; 1991. p. 159–76.
42. Hostetter M, Klein S. Segmenting populations to tailor services, improve care. The Commonwealth Fund; 2015.
43. Australian Bureau of Statistics. Estimates of Aboriginal and Torres Strait Islander Australians, June 2016. Released 31 August, 2018 edition. Canberra: ABS; 2018.
44. South Australian Cancer Registry: Cancer in South Australia 2015 - with projections to 2018. Adelaide, SA: South Australian Department for Health and Wellbeing; 2018.
45. Canadian Partnership Against Cancer. Cancer stage in performance measurement: a first look. Toronto: The Partnership; 2015.
46. Chadder J, Dewar R, Shack L, Nishri D, Niu J, Lockwood G. A first look at relative survival by stage for colorectal and lung cancers in Canada. *Curr Oncol*. 2016;23:119–24.
47. Murray C. Quantifying the burden of disease: the technical basis for disability-adjusted life years. *Bull World Health Organ*. 1994;72:429–45.
48. Murray CJ, Acharya AK. Understanding DALYs (disability-adjusted life years). *J Health Econ*. 1997;16:703–30.
49. Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, Aboyans V, Adetokunboh O, Afshin A, Agrawal A, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet*. 2017;390:1151–210.
50. Diaz A, Moore SP, Martin JH, Green AC, Garvey G, Valery PC. Factors associated with cancer-specific and overall survival among indigenous and non-indigenous gynecologic cancer patients in Queensland, Australia: a matched cohort study. *Int J Gynecol Cancer*. 2015;25:542–7.
51. South Australian Cancer Registry. Cancer in South Australia 2014—with projections to 2017. Adelaide, SA: South Australian Department for Health and Ageing; 2017.
52. Yerrell PH, Roder D, Cargo M, Reilly R, Banham D, Micklem JM, Morey K, Stewart HB, Stajic J, Norris M, et al. Cancer Data and Aboriginal Disparities (CanDAD)—developing an Advanced Cancer Data System for Aboriginal people in South Australia: a mixed methods research protocol. *BMJ Open*. 2016;6:e012505.
53. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin D, Whelan S, editors. *International classification of diseases for oncology*. 3rd ed. Geneva: World Health Organization; 2000.
54. Young JJ, Roffers S, Ries L, Fritz A, Hurlbut A, National Cancer Institute (Eds.). *SEER summary staging manual—2000: codes and coding instructions*. Bethesda: National Cancer Institute; 2001.
55. GBD. Causes of Death Collaborators: Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet*. 2016;2017(390):1151–210.
56. Brustugun OT, Moller B, Helland A. Years of life lost as a measure of cancer burden on a national level. *Br J Cancer*. 2014;111:1014–20.
57. Zhao Y, Malyon R. Life years at risk: a population health measure from a prevention perspective. *Int J Environ Res Public Health*. 2009;6:2387–96.
58. Papke LE, Wooldridge JM. Econometric methods for fractional response variables with an application to 401(k) plan participation rates. *J Appl Economet*. 1996;11:619–32.
59. StataCorp: Stata Statistical Software: Release 15.1. College Station, TX: StataCorp LP; 2017.
60. Sarfati D, Garvey G, Robson B, Moore S, Cunningham R, Withrow D, Griffiths K, Caron N, Bray F. Measuring cancer in Indigenous populations. *Ann Epidemiol*. 2018.
61. Steering Committee for the Review of Government Service Provision (SCRGPS). Report on Government Services 2018. Canberra: Productivity Commission; 2018.
62. Whitehead M. The concepts and principles of equity and health. Copenhagen: World Health Organization; 1990.
63. Lokuge K, Thurber K, Calabria B, Davis M, McMahon K, Sartor L, Lovett R, Guthrie J, Banks E. Indigenous health program evaluation design and methods in Australia: a systematic review of the evidence. *Aust N Z J Public Health*. 2017;41:480–2.
64. Health Performance Council. What's working, what's not: Review of the South Australian Health System Performance for 2011–2014. Adelaide: Government of South Australia; 2014.
65. Murray CJL, Lopez AD. Measuring global health: motivation and evolution of the Global Burden of Disease Study. *The Lancet*. 2017;390:1460–4.
66. Harper S, Lynch J. Methods for measuring cancer disparities: using data relevant to healthy people 2010 cancer-related objectives. Bethesda: National Cancer Institute; 2005.
67. Blakely T, Soeberg M, Carter K, Costilla R, Atkinson J, Sarfati D. Bias in relative survival methods when using incorrect life-tables: Lung and bladder cancer by smoking status and ethnicity in New Zealand. *Int J Cancer*. 2012;131:E974–82.
68. Grafféo N, Giorgi R. Non-matching life tables and impact. In: Satellite Symposium European Partnership for Action Against Cancer (EPAAC). ISPPA; 2014.
69. Dickman PW, Auvinen A, Voutilainen ET, Hakulinen T. Measuring social class differences in cancer patient survival: is it necessary to control for social class differences in general population mortality? A Finnish population-based study. *J Epidemiol Community Health*. 1998;52:727–34.
70. Withrow DR, Racey CS, Jamal S. A critical review of methods for assessing cancer survival disparities in indigenous population. *Ann Epidemiol*. 2016;26:579–91.
71. Withrow DR, Pole JD, Nishri ED, Tjepkema M, Marrett LD. Choice of relative or cause-specific approach to cancer survival analysis impacts estimates differentially by cancer type, population, and application: evidence from a Canadian population-based cohort study. *Popul Health Metrics*. 2017;15:24.
72. Howlader N, Ries LAG, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. *JNCI J Natl Cancer Inst*. 2010;102:1584–98.
73. Dwyer-Lindgren L, Stubbs RW, Bertozzi-Villa A, Morozoff C, Callender C, Finegold SB, Shirude S, Flaxman AD, Laurent A, Kern E, et al. Variation in

life expectancy and mortality by cause among neighbourhoods in King County, WA, USA, 1990–2014: a census tract-level analysis for the Global Burden of Disease Study 2015. *Lancet Public Health*. 2017;2:400–10.

74. Sheppard AJ, Chiarelli AM, Marrett LD, Nishri ED, Trudeau ME. Stage at diagnosis and comorbidity influence breast cancer survival in first nations women in Ontario, Canada. *Cancer Epidemiol Biomark Prev*. 2011;20:2160–7.
75. Santorelli ML, Hirshfield KM, Steinberg MB, Lin Y, Rhoads GG, Bandera EV, Demissie K. Racial differences in the effects of comorbidity on breast cancer-specific survival. *Cancer Causes Control*. 2017;28:809–17.
76. Wardliparingga Aboriginal Research Unit. South Australian Aboriginal Health Research Accord: Companion Document. Adelaide: South Australian Health and Medical Research Institute; 2014.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

